Table 6.
Completed and ongoing trials with at least 500 patients enrolled or planning to enroll
| Title | Recruitment | Enrollment | Interventions |
|---|---|---|---|
|
| |||
| CANVAS - CANagliflozin cardioVascular Assessment Study | Completed | 10,142 | Drugs: placebo, canagliflozin 100 mg, canagliflozin 300 mg |
| A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus | Completed | 5,813 | Drugs: placebo, canagliflozin 100 mg, canagliflozin 300 mg |
| Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes In Participants With Diabetic Nephropathy |
Active, not recruiting | 4,462 | Drugs: placebo, canagliflozin |
| CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin vs Glimepiride | Completed | 1,452 | Drugs: glimepiride, canagliflozin, metformin |
| Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus | Completed | 1,299 | Drugs: TA-7284-Low, TA-7284-High |
| The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis – DPP-4 Inhibitor Comparator Trial) | Completed | 1,284 | Drugs: placebo, canagliflozin, sitagliptin, metformin immediate release |
| A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise | Completed | 1,186 | Drugs: canagliflozin 100 mg, canagliflozin 300 mg, metformin XR |
| Efficacy and Safety of Semaglutide vs Canagliflozin as add- on to Metformin in Subjects With Type 2 Diabetes | Active, not recruiting | 784 | Drugs: semaglutide, canagliflozin, placebo (canagliflozin), placebo (semaglutide) |
| The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis – DPP-4 Inhibitor Second Comparator Trial) | Completed | 756 | Drugs: sitagliptin 100 mg, canagliflozin 300 mg, metformin, sulfonylurea |
| A Safety and Efficacy Study of Canagliflozin in Older Patients (55–80 Years of Age) With Type 2 Diabetes Mellitus | Completed | 716 | Drugs: placebo. canagliflozin 100 mg, canagliflozin 300 mg, antihyperglycemic agent(s) |
| A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulfonylurea | Completed | 678 | Drugs: placebo, canagliflozin 100 mg, canagliflozin 300 mg, metformin, sulfonylurea |
| The CANTATA-M (CANagliflozin Treatment and Trial Analysis – Monotherapy) Trial | Completed | 678 | Drugs: canagliflozin, placebo, sitagliptin |
| Genetics of Response to Canagliflozin | Enrolling by invitation | 650 | Drug: canagliflozin |
| TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes. | Recruiting | 600 | Drugs: sitagliptin - DPP4i, canagliflozin – SGLT2i, pioglitazone – TZD |
Abbreviations: SLGT-2, sodium-glucose cotransporter-2; TZD, thiazolidinedione.